{"url_path":"/sec/iova/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1425205/0001104659-26-080409-index.html","accession_number":"0001104659-26-080409","cik":"0001425205","ticker":"IOVA","issuer_name":"IOVANCE BIOTHERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1425205/0001104659-26-080409-index.html","primary_entity_key":"0001425205","primary_entity_name":"IOVANCE BIOTHERAPEUTICS, INC."},"word_count":88,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n[99.1](tm2618989d1_ex99-1.htm)\n \n[Iovance Biotherapeutics, Inc., Corporate Presentation\n– June 2026](tm2618989d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded as Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: July 2, 2026\n**Iovance Biotherapeutics, Inc.**\n\n \n \n \n\n \nBy:\n/s/ Frederick G. Vogt\n\n \n \nName:\nFrederick G. Vogt, Ph.D., J.D.\n\n \n \nTitle:\nInterim CEO and President, and General Counsel"}